Breaks Categories: News

TuesdayApr 21, 2026 2:08 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Biotech Valuation Trends 

Oncotelic Therapeutics (OTCQB: OTLC) was highlighted in a BioMedWire editorial examining how advancing drug pipelines are increasingly being recognized as measurable financial assets under U.S. GAAP, reflecting a broader shift in biotech valuation. The company was noted for leveraging its diversified pipeline and strategic holdings, including a 45% stake in GMP Bio, recently valued at more than $1 billion, as an example of how scientific progress and proximity to commercialization can directly enhance balance sheet value and investor perception. To view the full press release, visit https://ibn.fm/DPVZ8 About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to…

Continue Reading

TuesdayApr 21, 2026 1:51 pm

BioMedNewsBreaks — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) Launches Ibogaine Initiative Amid U.S. Policy Shift 

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.  Optimi Health (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) announced the launch of its Ibogaine Initiative to expand its Health Canada-licensed GMP manufacturing platform to include ibogaine production and supply, aligning with emerging U.S. regulatory momentum to accelerate psychedelic research and patient access. The move follows a recent U.S. executive order supporting clinical development and access pathways, including IND clearance for ibogaine trials, as Optimi positions itself to meet anticipated demand with regulated, pharmaceutical-grade supply while advancing its broader global strategy in MDMA and psilocybin therapies. To view the full press release, visit https://ibn.fm/EHpKr About Optimi Health Corp. Optimi Health…

Continue Reading

MondayApr 20, 2026 3:41 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation

Oncotelic Therapeutics (OTCQB: OTLC) is featured in recent BioMedWire editorial coverage highlighting a fundamental shift in biotechnology, where scientific progress is increasingly recognized as measurable financial value rather than purely as research expenditure. As clinical-stage assets advance toward commercialization, fair-value accounting frameworks under U.S. GAAP are enabling companies to reflect pipeline progress, probability of success and timing of market entry directly on the balance sheet. Within this evolving landscape, Oncotelic exemplifies the trend through its diversified oncology pipeline and strategic holdings, including its 45% stake in GMP Bio, recently measured at an enterprise value exceeding $1 billion, demonstrating how advancing science can materially strengthen financial positioning.  The BioMedWire editorial also situates Oncotelic alongside a group…

Continue Reading

MondayApr 20, 2026 3:12 pm

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Supports Executive Order To Accelerate Psychedelic Drug Development 

NRx Pharmaceuticals (NASDAQ: NRXP) welcomed a newly signed Executive Order aimed at accelerating medical treatments for serious mental illness, including expanded access to psychedelic therapies and faster regulatory pathways. The order directs the FDA to issue priority vouchers for qualifying breakthrough therapies and encourages broader use of clinical trial data and real-world evidence, aligning with NRx’s strategy as it advances its NRX-100 drug candidate and seeks regulatory support to address severe depression, PTSD and suicidality. To view the full press release, visit https://ibn.fm/OahNo About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for…

Continue Reading

MondayApr 20, 2026 3:00 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach 

By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader  Soligenix (NASDAQ: SNGX) is emphasizing the strategic importance of patient-centric drug development, as outlined by CEO Christopher J. Schaber in a Clinical Leader guest column, which explores how reformulating therapies can improve access, adherence, and real-world viability. Drawing on the company’s experience with SGX945, Schaber explains that early clinical trials revealed a disconnect between IV-based delivery and the daily realities of patients with chronic rare diseases, prompting a shift toward a more practical, home-based subcutaneous approach. According to Schaber, operational challenges such as travel burden, treatment scheduling, and patient retention should be…

Continue Reading

FridayApr 17, 2026 9:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Closes $10 Million Public Offering to Advance Cardiac Technology Commercialization

HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transaction completed on April 16, 2026. The offering, supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors, will fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes To view the full press release, visit https://ibn.fm/9iNYY About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the…

Continue Reading

ThursdayApr 16, 2026 9:49 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports FY 2025 Net Income of $249 Million 

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company focused on orphan oncology and advanced drug platforms, reported financial results for the fiscal year ended Dec. 31, 2025, with net income of approximately $249.0 million compared to a net loss of $4.8 million in FY 2024, primarily driven by a non-cash gain of approximately $365.4 million from the increased valuation of its GMP Biotechnology joint venture, partially offset by a deferred tax provision of $111.6 million. To view the full press release, visit https://ibn.fm/FciEs About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State…

Continue Reading

ThursdayApr 16, 2026 9:00 am

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands European Commercial Strategy Through Humanitas Collaboration

Regentis Biomaterials (NYSE American: RGNT) announced a collaboration with Humanitas Research Hospital in Milan, Italy, to support expanding clinical activities and commercial strategy for GelrinC(R) in Europe, where the product has CE Mark approval for knee cartilage repair. The collaboration includes Prof. Elizaveta Kon, an internationally recognized expert in cartilage regeneration and orthopedic innovation, who is expected to help lead development of Regentis’ European Centers of Excellence network, supporting surgeon education, clinical expertise and broader adoption of GelrinC(R) as the company advances commercialization. To view the full press release, visit https://ibn.fm/j7jt0 About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative…

Continue Reading

WednesdayApr 15, 2026 12:10 pm

BioMedNewsBreaks — Polyrizon Ltd. (NASDAQ: PLRZ) Closes $3.5 Million Registered Direct Offering and Concurrent Private Placement 

Polyrizon (NASDAQ: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional investor, generating approximately $3.5 million in gross proceeds. The transactions included the sale of 388,888 units or pre-funded units at a combined price of $9.00 per unit, consisting of ordinary shares or pre-funded warrants and common warrants, with additional pre-funded and common warrants issued in the private placement, as the company plans to use proceeds for working capital and general corporate purposes, while Aegis Capital Corp. acted as exclusive placement agent. To view…

Continue Reading

WednesdayApr 15, 2026 9:59 am

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Engages Venture Liquidity Providers for Market-Making Services 

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.  MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), a biotechnology company focused on AI-driven voice analytics for drug and alcohol intoxication detection, announced it has appointed Venture Liquidity Providers (VLP), subject to regulatory and final approvals, to provide market-making services aimed at maintaining an orderly trading market for its common shares. The service will be conducted through W.D. Latimer Co. Ltd. in compliance with Canadian Securities Exchange policies, with MindBio agreeing to pay $5,000 per month over a 12-month term, which may be terminated at any time, while both parties operate at arm’s length and…

Continue Reading